

RECEIVED
CENTRAL FAX CENTERUSSN 10/596,512
Docket No. PRD2170USPCT**REMARKS/ARGUMENTS****MAY 21 2008**


The Claims in the case are 1-5, 12, and 16. Claims 9-11 and 13-14 were cancelled in the preliminary amendment filed June 15, 2006. Claims 6-8, 15 and 17-18 are cancelled in this paper.

The Examiner has made a restriction requirement listing 9 groups. Applicants traverse the restriction, and propose that Groups III, IV, VI, and VIII be combined and searched together. This joinder would not present an unreasonable search burden on the examiner.

According to this modified proposal, Applicants would elect compounds wherein $a^1-a^2=a^3-a^4$ is N-CH=CH-CH and
Z is NH;
X¹ is NH;
and Y and X² groups are as defined in the application, except that X² is not the Het²⁰ moiety within Group IV.

Whether or not the Examiner not be agreeable to this proposal, Applicants elect Group VIII, because the species elected in any event, see below, has the substituents X² being O-Ak and Y being alk.

Applicants elect as ultimate species, the compound 1 having the name of 7H,19H-4,6-ethanediylidenepyrimido[4,5-b][13,1,4,6]benzoxatriazacyclopentadecine, 17-chloro-8,9,10,11,12,13-hexahydro-.



The structure of this compound is

USSN 10/596,512
Docket No. PRD2170USPCT

which is the compound prepared in Example B1. It falls within the Examiner's Group VIII. The more narrow definition of this group is within Claims 3 and 5, although all claims remaining in the application: 1-5, 12, and 16, read on the elected species.

CONCLUSION

Reconsideration of the restriction requirement in view of the amendments and arguments above is respectfully requested. Examination on the merits is respectfully requested.

Respectfully submitted,
Hesna J. Pfeiffer/
Hesna J. Pfeiffer, Reg. No. 22,640
Attorney for Applicants
(732) 524-2830

Johnson & Johnson
One Johnson & Johnson Plaza
New Brunswick, NJ 08933-7003
Date: May 21, 2008